The trading price of Avalo Therapeutics Inc (NASDAQ:AVTX) closed higher on Thursday, March 29, closing at $21.75, 357.89% higher than its previous close.
In examining the 52-week price action we see that the stock hit a 52-week high of $1130.40 and a 52-week low of $3.95. Over the past month, the stock has gained 389.86% in value.
Avalo Therapeutics Inc, whose market valuation is $17.40 million at the time of this writing, is expected to release its quarterly earnings report May 02, 2024 – May 06, 2024. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$4.8 per share this quarter, however they have predicted annual earnings per share of -$96 for 2023 and -$16.8 for 2024. It means analysts are expecting annual earnings per share growth of 91.00% this year and 82.50% next year.
Analysts have forecast the company to bring in revenue of $300k for the current quarter, with the likely lows of $300k and highs of $300k. The average estimate suggests sales will likely down by -66.50% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2023 is $1.7 million. The company’s revenue is forecast to drop by -90.60% over what it did in 2023.
A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Avalo Therapeutics Inc No upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest AVTX has a Hold on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Sell, while an average of long term indicators suggests that the stock is currently Hold.
A quick review shows that AVTX’s price is currently 347.83% off the SMA20 and 369.91% off the SMA50. The RSI metric on the 14-day chart is currently showing 92.24, and weekly volatility stands at 26.56%. When measured over the past 30 days, the indicator reaches 13.60%. Avalo Therapeutics Inc (NASDAQ:AVTX)’s beta value is currently sitting at 0.71, while the Average True Range indicator is currently displaying 2.51.
To see how Avalo Therapeutics Inc stock has been performing in comparison to its peers in the industry, here are the numbers: AVTX stock’s performance was 357.89% in the latest trading, and -94.79% in the past year.
An evaluation of the daily trading volume of Avalo Therapeutics Inc (NASDAQ:AVTX) indicates that the 3-month average is 98.06K. However, this figure has increased over the past 10 days to an average of 3.52 million.
Currently, records show that 0.80 million of the company’s shares remain outstanding. The insiders hold 0.00% of outstanding shares, whereas institutions hold 8.38%. The stats also highlight that short interest as of Mar 15, 2024, stood at 67180.0 shares, resulting in a short ratio of 2.19 at that time. From this, we can conclude that short interest is 8.38% of the company’s total outstanding shares. It is noteworthy that short shares in March were up slightly from the previous month’s figure, which was 63950.0. However, since the stock’s price has seen 139.01% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
